Conditions: Safety Healthy Subjects
Keywords: MEDI9314 Safety Tolerability Pharmacokinetics Immunogenicity
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 44
Healthy volunteers: yes

Brief summary:
This is a phase 1a randomized, blinded, placebo-controlled, single-ascending dose study to assess the safety and tolerability of MEDI9314 in healthy adult subjects

Detailed description:
This is a phase I study to assess the safety, tolerability pharmacokinetics, and immunogenicity of MEDI9314 following single dose administration to healthy subjects

Arms:
arm 1: single dose of MEDI9314 or placebo arm 2: single dose of MEDI9314 or placebo arm 3: single dose of MEDI9314 or placebo arm 4: single dose of MEDI9314 or placebo arm 5: single dose of MEDI9314 or placebo arm 6: single dose of MEDI9314 or placebo

Interventions: intervention 1: MEDI9314 intervention 2: placebo
Intervention descriptions: intervention 1: single dose of MEDI9314 intervention 2: single dose of placebo

Protocol document: